基于细胞和干细胞疗法的博士工程医学制造过程

拉夫堡大学在研究强度（REF2014）方面是英格兰排名前十的大学，并且有资格提交给REF的拉夫堡学术人员中有66％的杰出工作被评为“世界领先”。或“国际一流”，而全国平均水平为43％。<br>在选择拉夫堡进行研究时，您将与该领域的领导者一起工作。您将受益于我们的全面支持和指导，包括量身定制的职业建议，以帮助您在研究和未来职业中取得成功。<br>项目详情：<br>基于细胞和干细胞的疗法正在彻底改变医学治疗。诸如CAR-T细胞之类的免疫疗法可有效治疗先前的晚期疾病，并有望进入大众市场。但是，要实现具有成本效益
Loughborough University is a top-ten rated university in England for research intensity (REF2014) and an outstanding 66% of the work of Loughborough's academic staff who were eligible to be submitted to the REF was judged as ?world-leading? or ?internationally excellent?, compared to a national average figure of 43%.<br>In choosing Loughborough for your research, you'll work alongside academics who are leaders in their field. You will benefit from comprehensive support and guidance from our , including tailored careers advice, to help you succeed in your research and future career. <br>Project detail:<br>Cell and Stem Cell based therapies are revolutionising medical treatment. Immunotherapies such as CAR-T cells are effectively treating previously terminal diseases and are poised to reach mass markets. However, many challenges remain to achieve cost effective and high-quality mass production. This project will investigate the challenges involved in achieving consistent cell yields and cell quality in the manufacture of cell therapies. The successful applicant will have the opportunity to work with processes for manufacturing diverse cell products such as red cells, platelets, immunotherapies or neural repair amongst others. A range of state of the art bioreactor systems at various scales will be used to determine the impact of the manufacturing environment on the cell product. Novel modelling approaches will be applied to quantify the relationship between operation of manufacture and key outcomes such as cell population distributions and cell proliferation. In addition to the bioreactor technology the project will have access to a comprehensive analytical suite including high throughput multi-colour flow cytometry, high throughput nutrient and metabolite analysis, cytokine profiling and gene expression analysis. This project is positioned to make a real impact on industrialisation of cell therapies through delivering an understanding of manufacturing process control for a new class of paradigm shifting medicines.